Cyclo Therapeutics Inc. (CYTH)
NASDAQ: CYTH
· Real-Time Price · USD
0.72
-0.00 (-0.08%)
At close: Mar 25, 2025, 3:59 PM
Cyclo Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 870.73K | 1.13M | 1.13M | 1.08M | 951.81K | 908.5K | 1.33M | 1.38M | 1.77M | 1.73M | 1.42M | 1.59M | 1.15M | 964.77K | 935.77K |
Cost of Revenue | 2.66M | 2.68M | 1.77M | 945.42K | 84.64K | 78.9K | 132.66K | 138.93K | 191.82K | 181.46K | 137.95K | 156.08K | 102.86K | 91.77K | 74.56K |
Gross Profit | -1.79M | -1.55M | -645.26K | 130.98K | 867.17K | 829.6K | 1.2M | 1.24M | 1.58M | 1.54M | 1.28M | 1.43M | 1.04M | 873K | 861.21K |
Operating Income | -24.68M | -21.15M | -20.15M | -20.05M | -19.38M | -18.86M | -17.68M | -15.61M | -13.43M | -13.04M | -13.19M | -14.29M | -14.18M | -11.76M | -10.36M |
Interest Income | n/a | n/a | n/a | 47.00 | 2.52K | 4.14K | 8.18K | 8.13K | 5.65K | 4.03K | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -24.8M | -20.74M | -19.39M | -20.06M | -19.4M | -18.87M | -17.69M | -15.45M | -13.26M | -12.88M | -13.02M | -14.29M | -14.17M | -11.75M | -10.34M |
Net Income | -24.8M | -20.74M | -19.39M | -20.06M | -19.23M | -18.7M | -17.51M | 162.85B | 162.85B | 162.85B | 162.85B | -14.29M | -14.17M | -11.75M | -10.34M |
Selling & General & Admin | 6.74M | 5.9M | 5.76M | 5.95M | 6.5M | 6.78M | 7.54M | 7.82M | 7.73M | 8.32M | 7.44M | 6.52M | 6.22M | 4.38M | 3.9M |
Research & Development | 15.97M | 13.95M | 13.63M | 14.18M | 13.22M | 12.61M | 11.31M | 9M | 7.23M | 6.21M | 6.98M | 9.15M | 8.98M | 8.23M | 7.29M |
Other Expenses | -1.2M | -690.22K | 534.36K | n/a | 2.32M | 1.16M | 27.51K | 30.5K | 33.96K | 33.29K | 31.38K | 27.54K | 24.43K | 22.33K | 20.25K |
Operating Expenses | 22.88M | 19.6M | 19.51M | 20.18M | 20.25M | 19.69M | 18.88M | 16.85M | 14.99M | 14.57M | 14.45M | 15.7M | 15.22M | 12.63M | 11.22M |
Interest Expense | n/a | n/a | n/a | n/a | 184.97K | 184.97K | 184.97K | 162.87B | 162.87B | 162.87B | 162.87B | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 2.7K | 3.55K | 3.46K | 3.9K | 3.76K | 4.66K | 9.36K | 13.06K | 25K | 25.16K | 21.34K | 18.34K | 6.58K | 4.77K | 4.66K |
Cost & Expenses | 25.55M | 22.29M | 21.28M | 21.13M | 20.33M | 19.77M | 19.02M | 16.99M | 15.18M | 14.75M | 14.59M | 15.85M | 15.32M | 12.72M | 11.29M |
Income Tax Expense | 3.00 | 3.9K | 7.41K | 7.31K | -162.07K | -167.58K | -175.13K | -162.87B | -162.87B | -162.87B | -162.87B | 18.52K | -4.33K | -5.96K | -11.14K |
Shares Outstanding (Basic) | 28.73M | 28.64M | 28.59M | 24.87M | 16.19M | 14.04M | 11M | 8.46M | 8.45M | 8.42M | 8.41M | 6.45M | 6.45M | 6.37M | 5.33M |
Shares Outstanding (Diluted) | 28.73M | 28.64M | 28.59M | 24.87M | 16.19M | 14.04M | 11M | 8.46M | 8.45M | 8.42M | 8.41M | 6.45M | 6.45M | 6.37M | 5.33M |
EPS (Basic) | -0.9 | -0.88 | -1 | -1.31 | -1.65 | -1.86 | -1.94 | 19.36K | 19.36K | 19.36K | 19.36K | -2.35 | -2.42 | -2.67 | -3.71 |
EPS (Diluted) | -0.9 | -0.88 | -1 | -1.31 | -1.65 | -1.86 | -1.94 | 19.36K | 19.36K | 19.36K | 19.36K | -2.35 | -2.42 | -2.67 | -3.66 |
EBITDA | -24.67M | -21.14M | -20.14M | -20.03M | -19.37M | -18.85M | -17.68M | -15.6M | -13.41M | -13.02M | -13.17M | -14.27M | -14.16M | -11.74M | -10.34M |
EBIT | -24.68M | -21.15M | -20.15M | -20.05M | -19.38M | -18.86M | -17.68M | -15.61M | -13.41M | -13.02M | -13.17M | -14.27M | -14.18M | -11.76M | -10.36M |
Depreciation & Amortization | 11.35K | 13.99K | 16.63K | 19.28K | 19.33K | 19.64K | 19.56K | 19.48K | 18.82K | 17.9K | 18.02K | 16.83K | 16.03K | 14.94K | 13.2K |